Pfizer signed a deal worth up to $2.6 billion with Starna

Pfizer has agreed with China's Starna Therapeutics to develop three new therapies. The deal could be worth up to $2.6 billion.
Pfizer will pay $330 million upon signing the agreement. Starna could receive up to an additional $2.3 billion if the drugs successfully pass clinical trials, receive the necessary approvals, and sales reach agreed-upon targets.
The therapies are being developed to treat autoimmune diseases. The new method acts directly on immune cells within the body, whereas traditional CAR-T therapy first processes a patient's cells in a laboratory before using them for treatment.
Pfizer will have the rights to develop and sell these three programs outside of China. The company has recently been actively expanding its collaborations with Chinese biotech companies.
Source: Yahoo Finance
Get our latest market analysis and financial insights delivered straight to you. No spam — just the signal.





